Thi Minh Nghia Nguyen

Dr. Thi Minh Nghia Nguyen

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Open access
TNThi Minh Nghia Nguyen
Thi Minh Nghia Nguyen
LVLiliana Vicet-Muro
Liliana Vicet-Muro
DSDany Siverio-Mota
Dany Siverio-Mota
María Elisa Jorge RodríguezMaría Elisa Jorge Rodríguez
María Elisa Jorge Rodríguez
DGDulce M. González-Mosquera
Dulce M. González-Mosquera
ICIdelfonso Castañeda-Noa
Idelfonso Castañeda-Noa
Tamizaje fitoquímico y evaluación de la actividad sobre el sistema nervioso central del extracto etanólico de Eugenia clarensis Britton & P.Wilson.

Verified
Journal Article
Open access
PDF file
TNThi Minh Nghia Nguyen
Thi Minh Nghia Nguyen
MKMargarita KOndyli
Margarita KOndyli
HMHarald Mischak
Harald Mischak
FKFelix Lion Keller
Felix Lion Keller
Joachim BeigeJoachim Beige
Joachim Beige
JSJustyna Siwy
Justyna Siwy
Complement activation has been implicated in many kidney diseases, but it remains unclear whether urinary complement-derived peptides reflect kidney function beyond albuminuria and predict disease progression. We analyzed mass spectrometry-based urinary peptidomics data from 10,939 individuals with chronic kidney disease and healthy controls. Fifty-eight complement-derived peptides were identified, predominantly from complement factor B (CFB) and C3. Of these, fifty-two were significantly related to estimated glomerular filtration rate (eGFR) independently of albuminuria, mostly inversely. Several C3- and CFB-derived peptides were also associated with specific kidney disease etiologies. In a longitudinal analysis of 3964 individuals (median follow-up 2.91 years), 18 of these peptides were significantly related to a major adverse kidney event (MAKE, defined as ≥40% eGFR decline, end-stage kidney disease or death) after adjustment for clinical covariates, indicating prognostic information beyond traditional risk markers. In the independent test cohort, combining these peptides in a machine learning-based model and adding the resulting risk score to clinical parameters significantly improved MAKE prediction (AUC 0.801 vs. 0.778, p = 0.031). Thus, urinary complement-derived peptides provide independent and clinically relevant information on kidney function and disease progression, supporting their potential value in the identification of high-risk patients and guiding more personalized therapy.